[2] Ramirez-Ramirez MA，Sobrino-Cossio S，de la Mora-Levy JG，et al.Loss of expression of DNA mismatch repair proteins in aberrant crypt foci identified in vivo by magnifying colonoscopy in subjects with hereditary nonpolyposic and sporadic colon rectal cancer[J].J Gastrointest Cancer，2012，1 2(2): 209-214.
[2] Lipshultz SE，Rifai N，Dalton VM， et al.The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia[J].N Ensl J Med， 2004， 351(2): 145-153.
[3] Swain SM，Vici P.The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review [J].J Cancer Res Clin Oncol，2004， 130(1): 1-7.
[4] Venturini M，Michelotti A，Del Mastro L， et al.Multicenterrandomized controlled clinical trial to evaluate cadioprotection in women receiving epirubicin chemotherapy for advanced breast cancer[J].J Clin Oncol，1996，1 4(5): 3112-3120.
[5] Silverman LB，Gelber RD，Dalton VK， et al.Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01[J].Blood，2001，97 (5): 121l-1218.
[6] Albini A，Pennesi G，Donatelli F， et al.Cardiotoxicity of anticancer drugs: the need for eardio-oncology and cardiooncological prevention[J].J Natl Cancer Inst，2010，1 02(1): 14-25.
[7] Marry M，Espi M，Llombart A，et al.Multicenter randomized phase Ⅲ study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced /metastatic breast cancer patients treated with anthracyeline-based chemotherapy[J].Ann Oncol， 2006，1 7(4): 614-622.
[8] Lipshultz SE，Scully RE，Lipsitz SR， et al.Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukacmia: long-term follow-up of a prospective，randomised，multicentre trial [J].Lancet Oncol， 2010， 11(10): 950-961.
[9] Herman EH，Lipshultz SE，Ferrans VJ.The use of cardiac biomarkers to detect myocardial damage induced by chemotherapeutic agents[M]/ /Wu AHB.Cardiac markers.2nd ed.NJ: Humana Press，2003: 87-109.
[10] 庄海峰，张宇.右丙亚胺联合参麦注射液降低蒽环类药物心脏 毒性的临床研究[J].中国肿瘤临床，2 012，3 9(6): 348-351.